Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trial

ME Png, V Harris, J Grabey, ND Hart, BD Jani… - British Journal of …, 2024 - bjgp.org
Background: The cost-effectiveness of molnupiravir, an oral antiviral for early treatment of
SARS-CoV-2, has not been established in vaccinated populations. Aim: To evaluate the cost …
被引用次数：1 相关文章

Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of …

ME Png, V Harris, J Grabey, ND Hart… - The British journal of …, 2024 - eprints.soton.ac.uk
Background: the cost-effectiveness of molnupiravir, an oral antiviral for early treatment of
SARS-CoV-2, has not been established in vaccinated populations. Aim: to evaluate the cost …

Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of …

ME Png, V Harris, J Grabey, ND Hart, BD Jani… - British Journal of …, 2024 - ora.ox.ac.uk
BACKGROUND: The cost-effectiveness of molnupiravir, an oral antiviral for early treatment
of SARS-CoV-2, has not been established in vaccinated populations. AIM: To evaluate the …
[PDF] exeter.ac.uk

[PDF][PDF] Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of …

ME Png, V Harris, J Grabey, ND Hart, BD Jani… - Br J Gen …, 2024 - ore.exeter.ac.uk
BACKGROUND: The cost-effectiveness of molnupiravir, an oral antiviral for early treatment
of SARS-CoV-2, has not been established in vaccinated populations. AIM: To evaluate the …

Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of …

ME Png, V Harris, J Grabey, ND Hart… - British Journal of …, 2024 - orca.cardiff.ac.uk
Background: The cost-effectiveness of molnupiravir, an oral antiviral for early treatment of
SARS-CoV-2, has not been established in vaccinated populations. Aim: To evaluate the cost …

Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of …

ME Png, V Harris, J Grabey, N Hart… - British Journal of … - nottingham-repository.worktribe.com
Background: The cost-effectiveness of molnupiravir, an oral antiviral for early treatment of
SARS-CoV-2, has not been established in vaccinated populations. Aim: To evaluate the cost …

Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of …

ME Png, V Harris, J Grabey, ND Hart… - British Journal of …, 2024 - pure.qub.ac.uk
Background: The cost-effectiveness of molnupiravir, an oral antiviral for early treatment of
SARS-CoV-2, has not been established in vaccinated populations. Aim: To evaluate the cost …

Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of …

ME Png, V Harris, J Grabey, ND Hart… - The British Journal of …, 2024 - europepmc.org
Background The cost-effectiveness of molnupiravir, an oral antiviral for early treatment of
SARS-CoV-2, has not been established in vaccinated populations. Aim To evaluate the cost …

Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of …

ME Png, V Harris, J Grabey… - British Journal of …, 2024 - ora4-prd.bodleian.ox.ac.uk
BACKGROUND: The cost-effectiveness of molnupiravir, an oral antiviral for early treatment
of SARS-CoV-2, has not been established in vaccinated populations. AIM: To evaluate the …

Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of …

ME Png, V Harris, J Grabey, ND Hart… - The British journal of … - pubmed.ncbi.nlm.nih.gov
Background The cost-effectiveness of molnupiravir, an oral antiviral for early treatment of
SARS-CoV-2, has not been established in vaccinated populations. Aim To evaluate the cost …